Catalog No.
DHC04301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Plasma prekallikrein, KLK3, Fletcher factor, KLKB1, Kininogenin, Plasma kallikrein, PKK
Concentration
3.16 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P03952
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
X124-G01, DX-2930, CAS: 1426055-14-2
Clone ID
Lanadelumab
Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial, PMID: 30480729
Lanadelumab: A Review in Hereditary Angioedema, PMID: 31560114
Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks, PMID: 32452549
Lanadelumab, PMID: 31643419
Lanadelumab: First Global Approval, PMID: 30267321
Lanadelumab to treat hereditary angioedema, PMID: 31347612
Lanadelumab for the treatment of hereditary angioedema, PMID: 31657963
Lanadelumab, PMID: 30272897
Lanadelumab for the prevention of attacks in hereditary angioedema, PMID: 31721602
Hereditary Angioedema, PMID: 32187470
Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies, PMID: 30539362
A review of kallikrein inhibitor lanadelumab in hereditary angioedema, PMID: 31234673
Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy, PMID: 31695331
Pharmacoeconomic Review Report: Lanadelumab (Takhzyro): (Shire Pharma Canada ULC) [Internet], PMID: 32598112
Clinical Review Report Lanadelumab (Takhzyro): (Shire Pharma Canada ULC) [Internet], PMID: 32603039
Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study, PMID: 33258114
Hereditary and acquired angioedema, PMID: 31690390
Pharmacokinetics, Pharmacodynamics, and Exposure-Response of Lanadelumab for Hereditary Angioedema, PMID: 32407574
Prospective Analysis in Patients With HAE Under Prophylaxis With Lanadelumab: A Real-life Experience, PMID: 33026762
Antibodies to watch in 2019, PMID: 30516432
Lanadelumab (Takhzyro) for prevention of hereditary angioedema, PMID: 33755657
CADTH Canadian Drug Expert Committee Recommendation: Lanadelumab (Takhzyro — Shire Pharma Canada ULC): Indication: For the routine prevention of attacks of hereditary angioedema (HAE) in adolescents and adults [Internet], PMID: 32574003
Does hereditary angioedema make COVID-19 worse?, PMID: 32834893
[Lanadelumab : Future plasma-independent subcutaneous prophylaxis for bradykinin-mediated angioedema?], PMID: 28560465
The Effectiveness and Value of Lanadelumab and C1 Esterase Inhibitors for Prophylaxis of Hereditary Angioedema Attacks, PMID: 30698087
Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis, PMID: 28225674
Pharmacotherapy, PMID: 29777743
Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada, PMID: 34301329
An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension, PMID: 29043014
Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study, PMID: 34023564
Efficacy of lanadelumab in acquired angioedema with C1-inhibitor deficiency, PMID: 33556593
[Monoclonal antibodies: also for dermatologists!], PMID: 31903911
Indirect Comparison of Lanadelumab and Intravenous C1-INH Using Data from the HELP and CHANGE Studies: Bayesian and Frequentist Analyses, PMID: 33646565
Transition to lanadelumab-flyo from three medications for a hereditary angioedema patient with a variant in the SYTL2 gene: A case report, PMID: 33936709
Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation, PMID: 34082125
Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study, PMID: 34166549
Pediatric hereditary angioedema: what the otolaryngologist should know, PMID: 31592791
Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study, PMID: 34287942
Pharmaceutical Approval Update, PMID: 30559583
Biological therapy in hereditary angioedema: transformation of a rare disease, PMID: 31994957
[Monoclonal antibodies for monogenic diseases: a 2019 update], PMID: 31903913
[Hereditary angioedema due to C1-esterase inhibitor deficiency : novel approaches], PMID: 32270933
A lesson from a saboteur: High-MW kininogen impact in coronavirus-induced disease 2019, PMID: 32497257
A focus on the use of subcutaneous C1-inhibitor for treatment of hereditary angioedema, PMID: 32237900
Increased fibrinolysis-induced bradykinin formation in hereditary angioedema confirmed using stored plasma and biotechnological inhibitors, PMID: 31133046
Antibodies to watch in 2018, PMID: 29300693
Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research, PMID: 31645881
Antibodies to watch in 2017, PMID: 27960628
Recognition and Management of Hereditary Angioedema: Best Practices for Dermatologists, PMID: 34460082
Current medical management of hereditary angioedema: Follow-up survey of US physicians, PMID: 33122123
For research use only. Not for human or drug use.
